Although NLRP6 was reported to serve as a tumor suppressor in colorectal cancer, hepatocellular carcinoma, and gastric cancer [67–69], it was reported to restore immune evasion and radio-resistance in glioma through ASC/caspase-1/IL-1β axis [70]. Here, IL1B is linked to hepatocellular carcinoma.